Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination.
Forensic Sci Med Pathol
; 18(1): 74-79, 2022 03.
Article
in English
| MEDLINE | ID: covidwho-1499517
ABSTRACT
This report describes the clinical context and autopsy findings in the first reported fatal case of acute disseminated encephalomyelitis (ADEM), developed after being vaccinated using the Oxford/AstraZeneca COVID-19 vaccine. ADEM is a rare autoimmune disease, causing demyelination in the brain and spinal cord. A wide variety of precipitating factors can trigger ADEM, and it has long been known to be a rare adverse event following some types of vaccinations. Recently, ADEM has also been associated with COVID-19 infection and (very rarely) with COVID-19 vaccination. The reports of the latter however all pertain to living patients. Our case demonstrates that ADEM should be considered in patients developing neurological symptoms post COVID-19 vaccination, although that this adverse reaction is likely to remain extremely rare. Our report further emphasizes the added value of comprehensive post mortem investigation to confirm ante mortem diagnosis and to determine vaccination safety.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Encephalomyelitis, Acute Disseminated
/
COVID-19
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Forensic Sci Med Pathol
Journal subject:
Jurisprudence
/
Medicine
/
Pathology
Year:
2022
Document Type:
Article
Affiliation country:
S12024-021-00440-7
Similar
MEDLINE
...
LILACS
LIS